Investigation of selected 13 FDA approved drugs for TRPV1 Antagonism using molecular docking: An insight application for the treatment of Neuronal pain

• Published in: Research journal of pharmacy and technology 2020-11, Vol.13 (11), p.5328-5332
• Main Authors: Prashar, Pankaj, Kumar, Pardeep, Sood, Ankita, Gautam, Anamika, Kaur, Harmeet, Kaur, Arvinder, Ebrahim, Ruksaar, Sharma, Shubham, Melkani, Indu, Pandey, Narendra Kumar, Kumar, Bimlesh
• Format: Article
• Language: English
• Subjects: Amino acids; Binding sites; Diabetes; Drugs; FDA approval; Kinases; Ligands; Nervous system; Pain; Proteins; Software; Torture
• ISSN: 0974-3618; 0974-306X
• DOI: 10.5958/0974-360X.2020.00931.2

Transient receptor potential vanilloid type 1 (TRPV1) is one of the important target sites on which different drugs can act to prevent the pathogenesis of neuropathic pain. Neuropathic pain is a torture and unbearable pain occurs due to damage of somatosensory nervous system. Here in present investigation FDA approved drugs were evaluated to find out its propensity towards action on TRPV1 receptor. 13 FDA approved drugs were selected which were untouched act through TRPV1 receptor. Hence before going to start preclinical work molecular docking was performed to find out its action and binding towards isoform of TRPV1 i.e 2N27, 3J5R. the result of the study indicates that rutin and glimepiride showed better affinity among all selected drugs and rutin was better with respect to glimepiride. The binding site and interactions were also studied supported this study. Hence its can be concluded that Rutin and glimepiride exhibited best possible interaction by antagonizing the effect of TRPV1 receptor so can be consider for the treatment of neuropathic pain.